A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

empagliflozin in treatment pulmonary aerterial hypertension

On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.

DRUG

placebo in treatment pulmonary aerterial hypertension

On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.

Trial Locations (1)

100037

RECRUITING

Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

The Second Hospital of Shandong University

OTHER

collaborator

The First People's Hospital of Changzhou

OTHER

lead

China National Center for Cardiovascular Diseases

OTHER_GOV